Gabriel Roman Souza

Dr. Gabriel Roman Souza

Moffitt Cancer Center, Tampa, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2017 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AHAlexandre Hoeller
Alexandre Hoeller
CCCristiane Ribeiro De Carvalho
Cristiane Ribeiro De Carvalho
PFPedro Leite Costa Franco
Pedro Leite Costa Franco
DFDouglas Affonso Formolo
Douglas Affonso Formolo
AIAlexandre Kracker Imthon
Alexandre Kracker Imthon
RWRoger Walz
Roger Walz
(1) Objectives: Epilepsy disorder is likely to increase with aging, leading to an increased incidence of comorbidities and mortality. In spite of that, there is a lack of information regarding this issue and little knowledge of cognitive and emotional responses in aging subjects following epileptogenesis. We investigated whether and how aging distress epilepsy-related behavioral and biochemical outcomes are associated with cognition and emotion. (2) Methods: Young and middle-aged Wistar rats (3 or 12 months old) were treated with pentylenetetrazol (PTZ, 35 mg/kg) and injected on alternated days for 20 (young rats) and 32 days (middle-aged rats). Kindling was reached after two consecutive stages 4 plus one stage 5 or 6 in Racine scale. Control and kindled rats were evaluated in the elevated plus-maze (EPM) and object-recognition tests and their hippocampus was collected 24 h later for mitogen-activated protein kinases (MAPK) dosage. (3) Results: Middle-aged rats presented a higher resistance to develop kindling, with a decrease in the seizure severity index observed following the 4th and 9th PTZ injections. Middle-aged rats displayed an increased duration of the first myoclonic seizure and an increased latency to the first generalized seizure when compared to younger rats. The induction of kindling did not impair the animals’ performance (regardless of age) in the object-recognition task and the EPM test as well as it did not alter the hippocampal levels of MAPKs. (4) Significance: Our findings reveal that, despite age-related differences during epileptogenesis, middle-aged rats evaluated after kindling performed similarly during discriminative learning and emotional tasks in comparison to young animals, with no alteration of hippocampal MAPKs. Additional investigation must be carried out to explore the electrophysiological mechanisms underlying these responses, as well as the long-term effects displayed after kindling.

16 January 2022 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
GSGabriel Roman Souza
Gabriel Roman Souza
AAAhmed Abdalla
Ahmed Abdalla
DMDaruka Mahadevan
Daruka Mahadevan
Background: There is a paucity of literature that comprehensively analyzes previous and current clinical trials targeting neurofibromatoses-related tumors. This article aims to provide readers with drug development efforts targeting these tumors by analyzing translational and clinical findings. Methods: This systematic review was written according to the PRISMA guidelines. Inclusion criteria were clinical trials involving patients with neurofibromatosis type 1, type 2, or schwannomatosis that were treated with therapies targeting neurofibromatoses-associated tumors and that were registered on clinicaltrials.gov. In addition, a search was performed in PubMed, Web of Science, Google Scholar, and Embase European for articles fully describing these clinical trials. Results: A total of 265 clinical trials were registered and screened for eligibility. Ninety-two were included in this systematic review involving approximately 4636 participants. The number of therapies analyzed was more than 50. Drugs under investigation mainly act on the MAPK/ERK and PI3K/AKT/mTOR pathways, tumor microenvironment, or aberrantly over-expressed cell surface receptors. Selumetinib was the most effective medication for treating a neurofibromatosis type 1-associated tumor with approximately 68%–71% partial response for inoperable or progressive plexiform neurofibromas in children 2 years of age and older and bevacizumab for a neurofibromatosis type 2-related tumor with approximately 36%–41% partial response for vestibular schwannomas in patients 12 years of age and older. Conclusions: This systematic review presents the results of previous clinical investigations and those under development for neurofibromatoses-associated tumors. Clinicians may use this information to strategize patients to appropriate clinical trials.

11 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
FIFilip Ionescu
Filip Ionescu
JNJonathan Nguyen
Jonathan Nguyen
Carlos Manuel Moran-SeguraCarlos Manuel Moran-Segura
Carlos Manuel Moran-Segura
MPMahati Paravathaneni
Mahati Paravathaneni
GGG. Daniel Grass
G. Daniel Grass
Jad ChahoudJad Chahoud
Jad Chahoud
Penile squamous cell carcinoma (PSCC) is a rare and deadly malignancy. Therapeutic advances have been stifled by a poor understanding of disease biology. Specifically, the immune microenvironment is an underexplored component in PSCC and the activity of immune checkpoint inhibitors observed in a subset of patients suggests immune escape may play an important role in tumorigenesis. Herein, we explored for the first time the immune microenvironment of 57 men with PSCC and how it varies with the presence of human papillomavirus (HPV) infection and across tumor stages using multiplex immunofluorescence of key immune cell markers. We observed an increase in the density of immune effector cells in node-negative tumors and a progressive rise in inhibitory immune players such as type 2 macrophages and upregulation of the PD-L1 checkpoint in men with N1 and N2-3 disease. There were no differences in immune cell densities with HPV status.

17 December 2024 in European Journal of Haematology
Verified
Journal Article
Closed access
STShrinjaya B. Thapa
Shrinjaya B. Thapa
GSGabriel Roman Souza
Gabriel Roman Souza
MPMahati Paravathaneni
Mahati Paravathaneni
SCSean Cohen
Sean Cohen
TMTurab Mohammed
Turab Mohammed
DLDamian Abel Laber
Damian Abel Laber

24 November 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
GSGabriel Roman Souza
Gabriel Roman Souza
ZNZohra Nooruddin
Zohra Nooruddin
SLSophia Lee
Sophia Lee
LBLauren Boyle
Lauren Boyle
KLKana Tai Lucero
Kana Tai Lucero
SKSupreet Kaur
Supreet Kaur

15 April 2024 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
ATAndrew Ta
Andrew Ta
SKSupreet Kaur
Supreet Kaur
MMMichael Mader
Michael Mader
KFKathleen Franklin
Kathleen Franklin
MWMadison Williams
Madison Williams
ZNZohra Nooruddin
Zohra Nooruddin
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly male (97%) and white (75%). Median age of diagnosis for Black patients was 63 years vs 69 years for the entire cohort (p < 0.001). However, patients in each race/ethnicity subgroup presented with similar rates of stage I/II and III/IV disease, IPI score, cell of origin and HIT status. Outcomes analysis revealed similar treatment, response rates, median overall survival, and 1-, 3-, and 5-year survival across all subgroups. Hispanic patients had a 21% lower risk of death (HR = 0.79) than white patients, and Black patients had no significant difference in survival (HR = 0.98). This large retrospective study shows that when standard of care therapy is given within an equal access system, short-term treatment and survival outcomes are the same for all races.